The short version
- On January 1, 2026, Medicare reclassified skin substitutes as incident-to supplies and set one flat rate of about $127.14/cm² — roughly a 90% cut to product pay.
- It hits the physician office and hospital outpatient settings. Inpatient stays bundled, untouched.
- For plastic surgery and dermatology, the durable revenue was never the graft. It was the flap and the surgical work — and the rule leaves that alone.
What actually changed
The CY2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), issued October 31, 2025, did one structural thing: it stopped treating skin substitutes as separately payable biologicals and reclassified them as incident-to supplies.
Under the old methodology, products paid on average sales price plus a margin. List prices climbed, discounts widened, and the spread between acquisition cost and reimbursement became the revenue. That spread is what the rule eliminates. One flat rate now applies — about $127.14/cm² after the late-November technical correction — the same number regardless of which product you use or what it cost to buy.
Two details decide whether it hits you. The flat rate applies in the physician office (non-facility) and the hospital outpatient department. Inpatient stays bundled into the facility payment, as it always was. Generally speaking, if you apply grafts in the office, you’re exposed; if your volume is inpatient, you’re not.
What it means for plastic surgery
Here’s the reassuring part if your revenue is built on reconstruction: the money in a complex closure was never in the graft. It was in the flap.
A paraspinous or local muscle flap, an adjacent tissue transfer, a complex layered repair — those are surgical CPT codes, and the 2026 rule doesn’t touch them. They pay the same in 2026 as they did in 2025. The graft was always the adjunct, not the engine.
What changes is the economics of the adjunct. In the old world a skin substitute carried its own margin on top of the reconstruction. In the new world it doesn’t — the flat rate barely covers acquisition cost, and on a single wound the graft application usually bundles into the more comprehensive flap code anyway. Keep doing the surgical work. Just stop expecting the graft to contribute margin.
One more thing, plainly: stacking procedures on one wound does not multiply payment. On a single contiguous defect, the dominant flap is the payable code and the secondary closures fold into it. The practices billing the stack are the ones most exposed to recoupment.
What it means for dermatology
Dermatology’s exposure is different but real. Two areas carry it. Number one, post-Mohs and excisional reconstruction that uses a skin substitute for the defect. Number two, chronic wound and ulcer management in practices that run a wound care service line.
If either generated product-side revenue, that revenue is now flat-rated. For a derm group that built a wound care offering partly on skin substitute economics, this is the line item to model first. The clinical reasons to use these products may still hold. The financial reason to build a service line around them mostly doesn’t.
Why CMS did it
Because the old structure invited the behavior it got. Spending on skin substitutes ran into the billions, concentrated in office-based settings, driven by the price-versus-reimbursement spread rather than by clinical outcomes. CMS estimates the change removes about $19.6 billion in Medicare spending in 2026 alone. The reclassification is CMS closing that gap. Whatever you think of the method, the direction isn’t ambiguous, and it’s unlikely to reverse.
What to do before your next remittance cycle
- Quantify the exposure. Pull the share of your 2025 reimbursement that ran through skin substitute products. That number is the size of the hole.
- Re-anchor on the surgical work. Reconstruction, flaps, and complex repair are untouched. Make sure documentation and coding capture the surgical value fully — it’s carrying the line by itself now.
- Check your MAC’s LCDs. Coverage and application limits vary by contractor and are tightening alongside the payment change. Billing past the application caps invites denials and recoupment.
- Stop stacking on a single wound. One wound, one payable coverage code. Confirm your claims reflect that before an audit does it for you.
What survives, and what doesn’t
The clinical case for these products can still be sound. The financial case for building revenue around them is mostly gone. For specialty practices, the durable money was always in the surgical work — and that’s exactly what the 2026 rule leaves intact.
Generally speaking, if a meaningful share of your revenue ran through skin substitute applications, the move isn’t to fight the rule. It’s to re-anchor the P&L on the work the rule didn’t touch.
Frequently asked questions
What is the new skin substitute reimbursement rate for 2026?
About $127.14 per square centimeter after a late-November 2025 technical correction, paid as an incident-to supply. It replaces the prior ASP-based methodology and applies regardless of which product you use.
Does the 2026 skin substitute rule affect inpatient billing?
No. Inpatient use stays bundled into the facility (DRG) payment. The flat per-square-centimeter rate applies to the physician office (non-facility) setting and the hospital outpatient department under OPPS.
How does this change affect plastic surgery revenue?
The revenue in a complex closure lives in the flap and reconstruction codes, which are unchanged. The skin substitute graft no longer carries its own margin, but the surgical work that drives the revenue is untouched.
How does it affect dermatology practices?
Exposure is concentrated in post-Mohs reconstruction and chronic wound or ulcer service lines that billed skin substitute products. Those product-side margins are now flat-rated; the clinical use may still be justified, the revenue model isn’t.
Can I still bill multiple grafts on one wound?
No. One contiguous wound is one payable coverage code — the dominant procedure is paid and the rest fold into it. Multiple payments require genuinely separate, separately documented wounds, and even then the second is reduced. Stacking on one wound is the fastest path to recoupment.
Sizing the hole in your skin substitute revenue?
If a real share of your 2025 reimbursement ran through these products, that gap won’t close itself. We’ll quantify the exposure and tell you where the durable revenue actually sits.
This article is for general informational purposes and is not coding, billing, or legal advice. Verify current rules and your contractor policies before making operational decisions.
